Organon & Co. earnings releases OGN

Annual Quarterly

Organon & Co. last reported quarterly results on Apr 30, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $1.5 billion (-3.5% year over year) and diluted EPS of $0.55. It usually reports 30–43 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Apr 30, 2026 30 days after quarter end	Q1 FY2026 ended Mar 31, 2026	1,460 -3.5%	146 +67.8%	0.55 +66.7%
Feb 12, 2026 43 days after quarter end	Q4 FY2025 ended Dec 31, 2025	1,507 -5.3%	-205 -288.1%	-0.78 -287.1%
Nov 10, 2025 41 days after quarter end	Q3 FY2025 ended Sep 30, 2025	1,602 +1.3%	160 -55.4%	0.61 -55.8%
Aug 5, 2025 36 days after quarter end	Q2 FY2025 ended Jun 30, 2025	1,594 -0.8%	145 -25.6%	0.56 -25.3%
May 1, 2025 31 days after quarter end	Q1 FY2025 ended Mar 31, 2025	1,513 -6.7%	87 -56.7%	0.33 -57.7%
Feb 13, 2025 44 days after quarter end	Q4 FY2024 ended Dec 31, 2024	1,592 -0.4%	109 -80.0%	0.42 -80.3%
Oct 31, 2024 31 days after quarter end	— ended Sep 30, 2024	—	—	—
Aug 6, 2024 37 days after quarter end	— ended Jun 30, 2024	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: OGN (NYSE)
Fiscal year ends: December 31
Headquarters: Jersey City, NJ
SEC filer status: Large accelerated filer
SEC CIK: 1821825

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.